Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02818569 · ClinicalTrials.gov registry record · Phase 1
Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02818569: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT02818569 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02818569, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The broad objective of this investigation is to assess the safety and efficacy of oral therapy with dexmedetomidine for the induction and maintenance of restful sleep.
Interventions
- DRUG Dexmedetomidine
- OTHER Saline Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02818569
The ClinicalTrials.gov registry entry for NCT02818569 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dexmedetomidine is the first listed.
NCT02818569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02818569 about?
NCT02818569 is a clinical study titled "Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic". The broad objective of this investigation is to assess the safety and efficacy of oral therapy with dexmedetomidine for the induction and maintenance of restful sleep.
What is the current status of trial NCT02818569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2016-10. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02818569?
The interventions under investigation include: Dexmedetomidine (DRUG), Saline Placebo (OTHER).
Who is sponsoring clinical trial NCT02818569?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.